Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's ...

A huge first inning led the Northmor baseball team to a 16-5 win at Mount Gilead Friday evening. Taking the plate to open the game, Northmor sent 13 batters to the plate in the top of the first inning ...

Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...

Cantor Fitzgerald upgraded Gilead (GILD) to Overweight from Neutral with a price target of $125, up from $100, as the analyst took over ...

Whether you loved it or hated it, there was no questioning the show’s impact. “The Handmaid’s Tale” hauled in eight Emmy ...

Northmor claimed a second win this year over Mount Gilead in softball on Friday, jumping out to a 12-0 lead midway through the fourth inning and holding on for a 12-5 win.

The data show that a regimen based on Trodelvy and PD-1 inhibitor Keytruda (pembrolizumab) was better than Keytruda plus ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

Gilead Sciences, Inc. (GILD) announced on Monday that its late-stage study showed a combination of its drug Trodelvy with ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in ...

In some patients with advanced triple-negative breast cancer, Trodelvy plus Keytruda was associated with an improvement in disease progression.

Oppenheimer says Gilead (GILD) provided a “welcome surprise” this morning with ASCENT-04 hitting its primary endpoint. The firm was not ...